Science and Technology
Candidate combinations are identified via a rigorous process of antimicrobial and pharmacological screening, informed by extensive in-house expertise and driven by potential for rapid delivery to the market. Syntopix is able to bring to bear an integrated approach identifying antimicrobial synergies using industry standard techniques and predictive models of antimicrobial activity in the skin environment followed up by extensive microbiological evaluation.
Our lead compounds and combinations thereof are being moved through a development pipeline which includes patent protection and culminates in phase II clinical trials. Syntopix is currently seeking partnership opportunities to develop its products through to market.
Recent News
03/02/2010 07:00
Syntopix announces a Directorate change with Tom Bannatyne joining as Chairman.
12/11/2009 07:00
Syntopix announces positive results for its lead dermatological compound SYN0126
12/11/2009 07:00
Syntopix focuses development efforts around three specific core compounds
14/04/2009 13:13
EXCLUSIVE EVALUATION AGREEMENT
Syntopix signs an exclusive evaluation agreement with a major consumer healthcare company..